Glaucoma therapy mode of actions compared

Article

Although both latanoprost and timolol-dorzolamide fixed combination (TDFC) decrease 24-hour intraocular pressure (IOP) and enhance diastolic ocular perfusion pressure (DOPP) in primary open-angle glaucoma (POAG) patients, their mechanisms of action are different, according to study results published online by Investigative Ophthalmology and Visual Science.

Although both latanoprost and timolol-dorzolamide fixed combination (TDFC) decrease 24-hour intraocular pressure (IOP) and enhance diastolic ocular perfusion pressure (DOPP) in primary open-angle glaucoma (POAG) patients, their mechanisms of action are different, according to study results published online by Investigative Ophthalmology and Visual Science.

Luciano Quaranta, of the Clinica Oculistica at the Università degli Studi Brescia, Italy and colleagues conducted a randomized trial on patients with untreated POAG (n=27), who received either TDFC twice daily followed by latanoprost once daily or latanoprost twice daily followed by TDFC once daily for a period of six weeks. The team measured systolic (SBP) and diastolic (DBP) blood pressure as well as IOP, and then conducted variance analysis to establish the relationship between treatment regimens and DOPP.

TDFC reduced 24-hour IOP to 15.4±1.9 mmHg; both SBP and DBP were also reduced by this treatment regimen. Latanoprost reduced IOP to 16.7±1.7 mmHg, although neither SBP nor DBP were decreased. Both treatments increased DOPP equally.

Thus the team concluded that TDFC enhanced DOPP by reducing IOP sufficiently to counteract the DBP decrease; although latanoprost caused a smaller reduction in IOP than TDFC, after latanprost treatment DBP remained stable and so DOPP was increased.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.